Key result
Obesity shows no link to worse 5-year survival after minimally invasive mitral valve surgery.
Why the study?
High BMI makes minimally invasive mitral valve surgery more challenging, with some surgeons considering obesity a contraindication, but whether outcomes are genuinely worse was unclear.
Does obesity worsen operative outcomes and 5-year survival in patients undergoing minimally invasive mitral valve surgery?
Cohort (n=296)
Does obesity worsen operative outcomes and 5-year survival in patients undergoing minimally invasive mitral valve surgery?
Absolute Event Rate: 95.8% vs 95.5%
p-value: p=0.83
Obesity does not appear to adversely affect short- or mid-term outcomes in patients undergoing minimally invasive mitral valve surgery, suggesting it should not be considered an absolute contraindication.
Obesity may not preclude minimally invasive mitral valve surgery; this observational result leaves open effects on selection and requires prospective trials.
OBJECTIVES: High body mass index (BMI) makes minimally invasive mitral valve surgery (MIMVS) more challenging with some surgeons considering this a contraindication. We sought to determine whether this is because the outcomes are genuinely worse than those of non-obese patients. METHODS: This is a retrospective cohort study of all patients undergoing MIMVS ± concomitant procedures over an 8-year period. Patients were stratified into 2 groups: BMI ≥ 30 kg/m2 and BMI ˂ 30 kg/m2, as per World Health Organization definitions. Baseline characteristics, operative and postoperative outcomes and 5-year survival were compared. RESULTS: We identified 296 patients (BMI ≥30, n = 41, median 35.3, range 30-43.6; BMI <30, n = 255, median 26.2, range 17.6-29.9). The groups were well matched with regard to baseline characteristics. There was only 1 in-hospital mortality, and this was in the BMI < 30 group. There was no difference in repair rate for degenerative disease (100% vs 96.3%, P > 0.99 respectively) or operative durations [cross-clamp: 122 min interquartile range (IQR) 100-141) vs 125 min (IQR 105-146), P = 0.72, respectively]. There were only 6 conversions to sternotomy, all in non-obese patients. There was no significant difference in any other perioperative or post-operative outcomes. Using the Kaplan-Meier analysis, there was no significant difference in 5-year survival between the 2 groups (95.8% vs 95.5%, P = 0.83, respectively). CONCLUSIONS: In patients having MIMVS, there is insufficient evidence to suggest that obesity affects either short- or mid-term outcomes. Obesity should therefore not be considered as a contraindication to this technique for experienced teams.
No takes yet. Share an insight, caveat, or question.
Aljanadi et al. (2020) conducted a cohort in Mitral valve disease requiring minimally invasive surgery (n=296). Obesity (BMI ≥ 30 kg/m2) vs. Non-obese (BMI < 30 kg/m2) was evaluated on 5-year survival (p=0.83). Obesity (BMI ≥ 30 kg/m2) was not associated with worse 5-year survival compared to non-obese patients undergoing minimally invasive mitral valve surgery (95.8% vs 95.5%, P=0.83).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: